Abstract
Introduction Migraine is a heavily debilitating disease that ranks second place in Global Burden Disease. It is estimated that around 1 billion of people suffer from it. It also has a significant negative impact on health-related quality of life (HRQoL) of patients and can affect their social, occupational, academic and familial life. Thus, it is crucial that all of the patients receive an effective treatment. Objectives This article aims to review the most recent advances in treatment of migraine. Methods A Literature review of articles published in Pubmed between 2000 and 2024 using the following words ‘migraine’, ‘treatment advances’, ‘CGRP receptor antagonists’, ‘serotonin receptor agonists’, ‘lasmiditan’, ‘zavegepant’, ‘rimegepant’. Results Literature search provides several concepts of advances in migraine treatment. Apart from behavioral treatment, new drugs targeting calcitonin gene related receptors (CGRP) and serotonin receptors agonists are emerging. Conclusion Migraine is a debilitating disease which significantly reduces health related quality of life in patients. New drugs targeting calcitonin gene related receptors (CGRP) and serotonin receptors agonists give a chance for more effective and tailored treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
